Approval Year
Substance Class |
Concept
|
Record UNII |
F94OW58Y8V
|
Record Status |
non-approved
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
881322
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
NCI_THESAURUS |
C261
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
NDF-RT |
N0000007529
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
NDF-RT |
N0000175935
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
WHO-ATC |
S01AA26
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
WHO-ATC |
J01FA10
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
WHO-VATC |
QS01AA26
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
WHO-ATC |
J01RA07
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
NDF-RT |
N0000007529
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.2
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
NDF-RT |
N0000007529
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
LIVERTOX |
NBK548434
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
||
|
WHO-VATC |
QJ01FA10
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Y-83
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
PRIMARY | |||
|
D017963
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
PRIMARY | |||
|
DB00207
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
PRIMARY | |||
|
Azithromycin
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
PRIMARY | |||
|
276
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
PRIMARY | |||
|
AZITHROMYCIN
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL529
Created by
admin on Fri Dec 15 16:28:05 GMT 2023 , Edited by admin on Fri Dec 15 16:28:05 GMT 2023
|
PRIMARY |
This is a sub-concept of substance:
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
SUBSTANCE -> SUB_CONCEPT |
|
||
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MAXIMUM TOLERATED DOSE | TOXICITY |
|
STREPTOCOCCALl TONSILLITIS/PHARYNGITIS |
|
||
Tmax | PHARMACOKINETIC |
|
FORMULATION: IMMEDIATE RELEASE PHARMACOKINETIC |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: RESISTANT (R) |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: HAEMOPHILUS SP. |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
INTRAVENOUS PHARMACOKINETIC |
|
||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
FORMULATION: EXTENDED RELEASE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: ORAL, IV |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: SUSCEPTIBLE (S) |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: SUSCEPTIBLE (S) |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: S. AUREUS |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: ADULTS |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: RESISTANT (R) |
|
||
Tmax | PHARMACOKINETIC |
|
FORMULATION: EXTENDED RELEASE |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: INTERMEDIATE (I) |
|
||
This is a sub-concept of substance: